Preview Mode Links will not work in preview mode
  1. All Episodes
  2. Endocrine-Resistant HR-Positive Metastatic Breast Cancer — An Interview with Dr Hope S Rugo on Optimal Management (Companion Faculty Lecture)

Endocrine-Resistant HR-Positive Metastatic Breast Cancer — An Interview with Dr Hope S Rugo on Optimal Management (Companion Faculty Lecture)

Jul 28, 2025

Featuring a slide presentation and related discussion from Dr Hope S Rugo, including the following topics:

  • Current treatment landscape for and outcomes in HR-positive, HER2-negative metastatic breast cancer (mBC) (0:00)
  • Trastuzumab deruxtecan for HER2-low and HER2-ultralow mBC (7:49)
  • Sacituzumab govitecan for HR-positive, HER2-negative mBC (20:44)
  • Datopotamab deruxtecan for HR-positive, HER2-negative mBC (27:29)
  • Novel antibody-drug conjugates under investigation for HR-positive mBC (33:19)

CME information and select publications